Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Literature DB >> 26075821

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Camille Guillerey, Lucas Ferrari de Andrade, Slavica Vuckovic, Kim Miles, Shin Foong Ngiow, Michelle C R Yong, Michele W L Teng, Marco Colonna, David S Ritchie, Marta Chesi, P Leif Bergsagel, Geoffrey R Hill, Mark J Smyth, Ludovic Martinet.

Abstract

Entities: Disease Gene

Year: 2015 PMID： 26075821 PMCID： PMC4563701 DOI： 10.1172/JCI82646

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

Keyword Cloud
Cited

× No keyword cloud information.

19 in total

1. Preclinical animal models of multiple myeloma.

Authors: Seint T Lwin; Claire M Edwards; Rebecca Silbermann
Journal: Bonekey Rep Date: 2016-02-03

2. Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis.

Authors: Emilie T E Gross; Semi Han; Prasantha Vemu; Carlos D Peinado; Martin Marsala; Lesley G Ellies; Jack D Bui
Journal: Oncoimmunology Date: 2016-12-14 Impact factor: 8.110

3. Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy.

Authors: Erin W Meermeier; Seth J Welsh; Meaghen E Sharik; Megan T Du; Victoria M Garbitt; Daniel L Riggs; Chang-Xin Shi; Caleb K Stein; Marco Bergsagel; Bryant Chau; Matthew L Wheeler; Natalie Bezman; Feng Wang; Pavel Strop; P Leif Bergsagel; Marta Chesi
Journal: Cancer Discov Date: 2021-05-05 Impact factor: 39.397

4. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.

Authors: Huan Liu; Jin He; Su Pin Koh; Yuping Zhong; Zhiqiang Liu; Zhiqiang Wang; Yujin Zhang; Zongwei Li; Bjorn T Tam; Pei Lin; Min Xiao; Ken H Young; Behrang Amini; Michael W Starbuck; Hans C Lee; Nora M Navone; Richard E Davis; Qiang Tong; P Leif Bergsagel; Jian Hou; Qing Yi; Robert Z Orlowski; Robert F Gagel; Jing Yang
Journal: Sci Transl Med Date: 2019-05-29 Impact factor: 17.956

5. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Authors: Michael Boyiadzis; Michael R Bishop; Rafat Abonour; Kenneth C Anderson; Stephen M Ansell; David Avigan; Lisa Barbarotta; Austin John Barrett; Koen Van Besien; P Leif Bergsagel; Ivan Borrello; Joshua Brody; Jill Brufsky; Mitchell Cairo; Ajai Chari; Adam Cohen; Jorge Cortes; Stephen J Forman; Jonathan W Friedberg; Ephraim J Fuchs; Steven D Gore; Sundar Jagannath; Brad S Kahl; Justin Kline; James N Kochenderfer; Larry W Kwak; Ronald Levy; Marcos de Lima; Mark R Litzow; Anuj Mahindra; Jeffrey Miller; Nikhil C Munshi; Robert Z Orlowski; John M Pagel; David L Porter; Stephen J Russell; Karl Schwartz; Margaret A Shipp; David Siegel; Richard M Stone; Martin S Tallman; John M Timmerman; Frits Van Rhee; Edmund K Waller; Ann Welsh; Michael Werner; Peter H Wiernik; Madhav V Dhodapkar
Journal: J Immunother Cancer Date: 2016-12-20 Impact factor: 13.751

6. Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells.

Authors: Beatrice Zitti; Rosa Molfetta; Cinzia Fionda; Linda Quatrini; Helena Stabile; Mario Lecce; Valeria de Turris; Maria Rosaria Ricciardi; Maria Teresa Petrucci; Marco Cippitelli; Angela Gismondi; Angela Santoni; Rossella Paolini
Journal: Sci Rep Date: 2017-09-05 Impact factor: 4.379

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

1. Preclinical animal models of multiple myeloma.

2. Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis.

3. Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy.

4. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.

5. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

6. Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells.

Review 7. Mouse models of multiple myeloma: technologic platforms and perspectives.

Review 8. NK Cell Dysfunction and Checkpoint Immunotherapy.

9. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.

Review 10. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.